Tags

Type your tag names separated by a space and hit enter

[Complete remission achieved by L-asparaginase, vincristine and prednisolone (LVP) therapy in secondary leukemia (M5a type) with an MLL gene rearrangement].
Rinsho Ketsueki. 1997 Feb; 38(2):135-41.RK

Abstract

A 16-year-old boy was operated upon for synovial sarcoma of the right thigh and underwent chemotherapy consisted of adriamycin (320 mg), cisplatin (780 mg), etoposide (4,200 mg) and ifosfamide (30,000 mg). He developed secondary leukemia 18 months after the chemotherapy. Acute lymphoblastic leukemia (L3) was initially diagnosed because of poor staining of alpha-naphtyl butylate esterase and induction chemotherapy with the LVP regimen (L-asparaginase 5,000 U/m2 day 8-21, vincristine 1.5 mg/ m2 day 1, 6, 11, 16, 21, 26, prednisolone 40 mg/m2 day 1-28) was performed. After the therapy was initiated, the leukemia was finally diagnosed as acute momocytic leukemia (M5a) because of the following data; blasts were positive for CD33 and HLA-DR and negative for CD10, CD19 and CD20; serum lysozyme was 104.0 micrograms/ml; re-evaluation revealed that blasts were strongly positive for alpha naphtyl butyrate esterase in a small part of the slides; 95% of the bone marrow cells showed t (9; 11) chromosomal aberration; gene rearrangement was positive for MLL and negative for JH, JK and TCR C beta 1. Nevertheless, complete remission was obtained after 1 course of LVP therapy. He received bone marrow transplantation from an unrelated volunteer donor after 3 courses of consolidation therapy. He has remained in complete remission for 16 months.

Authors+Show Affiliations

Department of Hematology/Chemotherapy, Kanagawa Cancer Center.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
English Abstract
Journal Article

Language

jpn

PubMed ID

9059068

Citation

Tomita, N, et al. "[Complete Remission Achieved By L-asparaginase, Vincristine and Prednisolone (LVP) Therapy in Secondary Leukemia (M5a Type) With an MLL Gene Rearrangement]." [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology, vol. 38, no. 2, 1997, pp. 135-41.
Tomita N, Fujita H, Koharazawa H, et al. [Complete remission achieved by L-asparaginase, vincristine and prednisolone (LVP) therapy in secondary leukemia (M5a type) with an MLL gene rearrangement]. Rinsho Ketsueki. 1997;38(2):135-41.
Tomita, N., Fujita, H., Koharazawa, H., Maruta, A., Kodama, F., Yamamoto, T., Kobayashi, S., & Okubo, T. (1997). [Complete remission achieved by L-asparaginase, vincristine and prednisolone (LVP) therapy in secondary leukemia (M5a type) with an MLL gene rearrangement]. [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology, 38(2), 135-41.
Tomita N, et al. [Complete Remission Achieved By L-asparaginase, Vincristine and Prednisolone (LVP) Therapy in Secondary Leukemia (M5a Type) With an MLL Gene Rearrangement]. Rinsho Ketsueki. 1997;38(2):135-41. PubMed PMID: 9059068.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Complete remission achieved by L-asparaginase, vincristine and prednisolone (LVP) therapy in secondary leukemia (M5a type) with an MLL gene rearrangement]. AU - Tomita,N, AU - Fujita,H, AU - Koharazawa,H, AU - Maruta,A, AU - Kodama,F, AU - Yamamoto,T, AU - Kobayashi,S, AU - Okubo,T, PY - 1997/2/1/pubmed PY - 1997/2/1/medline PY - 1997/2/1/entrez SP - 135 EP - 41 JF - [Rinsho ketsueki] The Japanese journal of clinical hematology JO - Rinsho Ketsueki VL - 38 IS - 2 N2 - A 16-year-old boy was operated upon for synovial sarcoma of the right thigh and underwent chemotherapy consisted of adriamycin (320 mg), cisplatin (780 mg), etoposide (4,200 mg) and ifosfamide (30,000 mg). He developed secondary leukemia 18 months after the chemotherapy. Acute lymphoblastic leukemia (L3) was initially diagnosed because of poor staining of alpha-naphtyl butylate esterase and induction chemotherapy with the LVP regimen (L-asparaginase 5,000 U/m2 day 8-21, vincristine 1.5 mg/ m2 day 1, 6, 11, 16, 21, 26, prednisolone 40 mg/m2 day 1-28) was performed. After the therapy was initiated, the leukemia was finally diagnosed as acute momocytic leukemia (M5a) because of the following data; blasts were positive for CD33 and HLA-DR and negative for CD10, CD19 and CD20; serum lysozyme was 104.0 micrograms/ml; re-evaluation revealed that blasts were strongly positive for alpha naphtyl butyrate esterase in a small part of the slides; 95% of the bone marrow cells showed t (9; 11) chromosomal aberration; gene rearrangement was positive for MLL and negative for JH, JK and TCR C beta 1. Nevertheless, complete remission was obtained after 1 course of LVP therapy. He received bone marrow transplantation from an unrelated volunteer donor after 3 courses of consolidation therapy. He has remained in complete remission for 16 months. SN - 0485-1439 UR - https://www.unboundmedicine.com/medline/citation/9059068/[Complete_remission_achieved_by_L_asparaginase_vincristine_and_prednisolone__LVP__therapy_in_secondary_leukemia__M5a_type__with_an_MLL_gene_rearrangement]_ L2 - https://antibodies.cancer.gov/detail/CPTC-HLA-DPB1-2 DB - PRIME DP - Unbound Medicine ER -